The CEBPB-GPD1L-ether lipid-Akt-CPT1A axis is proposed as a new druggable driver in ccRCC integrating epigenetics, transcription, intermediary metabolism and oncogenic signaling. This evidence concerns the gene GPD1L and nonpapillary renal cell carcinoma.